Dr. O'Shaughnessy on Negative TNBC Iniparib Results

Joyce A. OShaughnessy, MD
Published: Tuesday, Aug 23, 2011

Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that iniparib's mechanism of action (MOA) is still under intensive study and has been under examination since the drug was first discovered.

Despite its recent negative triple negative breast cancer (TNBC) trial results O'Shaughnessy believes iniparib will become interesting once again. She describes that in a physiological concentration you do no inhibit PARP but in higher concentrations inhibition does occur. She believes that once the MOA is fully understood more options will be available.

Other trials are currently underway examining iniparib; options are becoming clear, such as its single agent use in BRCA2 mutated pancreatic cancer. It is still being investigated in TNBC, which O'Shaughnessy believes is still too broad of a category. A subset of patients in the TNBC trial demonstrated a benefit to the drug; trials still need to be conducting to pinpoint this subset of patients.
Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that iniparib's mechanism of action (MOA) is still under intensive study and has been under examination since the drug was first discovered.

Despite its recent negative triple negative breast cancer (TNBC) trial results O'Shaughnessy believes iniparib will become interesting once again. She describes that in a physiological concentration you do no inhibit PARP but in higher concentrations inhibition does occur. She believes that once the MOA is fully understood more options will be available.

Other trials are currently underway examining iniparib; options are becoming clear, such as its single agent use in BRCA2 mutated pancreatic cancer. It is still being investigated in TNBC, which O'Shaughnessy believes is still too broad of a category. A subset of patients in the TNBC trial demonstrated a benefit to the drug; trials still need to be conducting to pinpoint this subset of patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x